Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Ivabradine, a novel heart rate slower: is it a sword of double blades in patients with idiopathic dilated cardiomyopathy?Rayan M; Tawfik M; Alabd A; Gamal AAnadolu Kardiyol Derg 2011[Aug]; 11 (5): 402-6OBJECTIVE: To prospectively assess the safety and efficacy of ivabradine in patients with idiopathic dilated cardiomyopathy. METHODS: We included 35 patients with idiopathic dilated cardiomyopathy with an ejection fraction (EF) <40% and heart rate >70 beats/min despite optimal medical therapy, according to the international guidelines in this prospective, non-randomized, single-arm, open-label safety study. Ivabradine was used as an add-on therapy to the maximally tolerated b-blocker in an increasing titrated dose till a target dose of 15 mg/day or resting heart rate of 60 beats/min for 3 months. During follow-up period the safety, patient tolerance and efficacy of this drug were assessed. All patients underwent 12-lead resting electrocardiography and Holter monitoring at inclusion and after 3 months. Statistical analysis was accomplished using paired t-test and Pearson correlation analysis. RESULTS: We found a significant reduction in the resting heart rate by a mean of 25.9 +/- 9.4%, without a significant change of blood pressure. There was no prolongation of PR, QTc or QRS durations. Ventricular ectopic activity showed significant reduction (p<0.001). There was a significant correlation between the resting heart rate, NYHA and left ventricular ejection fraction (p<0.001 for both). One patient developed photopsia and decompensation was observed in another patient. CONCLUSION: Ivabradine is a safe and effective drug in reducing resting heart rate, improving NYHA functional class without undesirable effects on conduction parameters or ectopic activity.|Adult[MESH]|Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH]|Anti-Arrhythmia Agents/pharmacology/standards/*therapeutic use[MESH]|Benzazepines/pharmacology/standards/*therapeutic use[MESH]|Carbazoles/therapeutic use[MESH]|Cardiomyopathy, Dilated/*drug therapy[MESH]|Cardiotonic Agents/therapeutic use[MESH]|Carvedilol[MESH]|Digoxin/therapeutic use[MESH]|Diuretics/therapeutic use[MESH]|Drug Therapy, Combination[MESH]|Echocardiography[MESH]|Electrocardiography[MESH]|Electrocardiography, Ambulatory[MESH]|Female[MESH]|Heart Rate/*drug effects[MESH]|Humans[MESH]|Ivabradine[MESH]|Male[MESH]|Middle Aged[MESH]|Propanolamines/therapeutic use[MESH]|Prospective Studies[MESH]|Spironolactone/therapeutic use[MESH]|Vasodilator Agents/therapeutic use[MESH]|Ventricular Premature Complexes/drug therapy[MESH] |